Pipettes in a row

Research Pipeline

With many potential new therapies currently in clinical trials, our goal is to be the industry leader in specialty care. We remain focused on discovering scientific breakthroughs to address complex, debilitating diseases.

Explore highlights of our research and development pipeline across our five areas of focus.

Items marked with ^ are being developed in collaboration with Regeneron, are being developed in collaboration with Sangamo Therapeutics,  are being developed in collaboration with Roche, are being developed in collaboration with SOBI, ✿ are being developed in collaboration with Revolution Medicines, ⚙ are being developed in collaboration with BioNtech, are being developed in collaboration with Immunext, are being developed in collaboration with Denali, ➤ are being developed in collaboration with Lead Pharma and Items shown with a ✜ denote a Phase 1/2 trial. Items shown with a denote a Phase 2/3 trial. Items shown with ▼ denote the INN in the US is cemiplimab-rwlc. Items shown with ♠ denote opt in rights product for which rights have not been exercised yet. Items shown with ❒ denote identification of out-licensing partner ongoing. Items shown with ♣ denotes Pfizer product.

Product Candidate Technology Phase I Phase II Phase III Current Phase

Rare Diseases

Eliglustat
Gaucher disease Type 1, ERT switch Pediatric
small molecule Eliglustat Gaucher disease Type 1 Pediatric, ERT switch - Phase I - 100% of progress Eliglustat Gaucher disease Type 1 Pediatric , ERT switch - Phase II - 100% of progress Eliglustat Gaucher disease Type 1 Pediatric , ERT switch - Phase III - 50% of progress PHASE III
Avalglucosidase alfa
Pompe disease
protein-based therapy Avalglucosidase alfa Pompe disease, 2nd generation enzyme - Phase I - 100% of progress Avalglucosidase alfa Pompe disease, 2nd generation enzyme - Phase II - 100% of progress Isatuximab 3L Relapsed Refractory Multiple Myeloma (ICARIA)- Phase III - 100% of progress PHASE III
Venglustat
GM2 Gangliosidosis
small molecule Venglustat GM2 Gangliosidosis - Phase I - 100% of progress Venglustat GM2 Gangliosidosis - Phase II - 100% of progress Venglustat GM2 Gangliosidosis - Phase III - 25% of progress PHASE III
Venglustat
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
small molecule Venglustat Autosomal Dominant Polycystic Kidney Disease - Phase I - 100% of progress Venglustat Autosomal Dominant Polycystic Kidney Disease - Phase II - 100% of progress Venglustat Autosomal Dominant Polycystic Kidney Disease - Phase III - 25% of progress PHASE III
Olipudase Alfa†
Acid Sphingomyelinase Deficiency (ASMD) - Adult+Pediatric
protein-based therapy Olipudase Alfa† Acid Sphingomyelinase Deficiency (ASMD) - Phase I - 100% of progress Olipudase Alfa† Acid Sphingomyelinase Deficiency (ASMD) - Phase II - 100% of progress Olipudase Alfa† Acid Sphingomyelinase Deficiency (ASMD) - Phase III - 0% of progress PHASE II
Venglustat
Fabry disease
small molecule venglustat Fabry disease - Phase I - 100% of progress venglustat Fabry disease - Phase II - 100% of progress venglustat Fabry disease - Phase III - 0% of progress PHASE II
Venglustat
Gaucher disease Type 3
small molecule venglustat Gaucher Type 3 - Phase I - 100% of progress venglustat Gaucher Type 3 - Phase II - 50% of progress venglustat Gaucher Type 3 - Phase III - 0% of progress PHASE II
SAR339375
Alport Syndrome
miRNA-21  SAR339375 Alport Syndrome - Phase II - 100% of progress SAR339375 Alport Syndrome - Phase II - 50% of progress SAR339375 Alport Syndrome - Phase III - 0% of progress PHASE II

Rare Blood Disorders

Sutimlimab
Cold agglutinin disease
 mAb to C1s Fitusiran* Hemophilia A & B - Phase I - 100% of progress Fitusiran* Hemophilia A & B - Phase II - 100% of progress Isatuximab 3L Relapsed Refractory Multiple Myeloma (ICARIA)- Phase III - 100% of progress PHASE III 
Fitusiran
Hemophilia A & B
RNAi Fitusiran* Hemophilia A & B - Phase I - 100% of progress Fitusiran* Hemophilia A & B - Phase II - 100% of progress Fitusiran* Hemophilia A & B - Phase III - 50% of progress PHASE III
Fitusiran
Hemophilia A & B - pediatric
RNAi Fitusiran* Hemophilia A & B-pediatric - Phase I - 100% of progress Fitusiran* Hemophilia A & B-pediatric - Phase II - 100% of progress Fitusiran* Hemophilia A & B-pediatric - Phase III - 50% of progress PHASE III
BIVV001
Hemophilia A
Extended Half Life Factor BIVV001 Hemophilia A - Phase I - 100% of progress BIVV001 Hemophilia A - Phase II - 100% of progress BIVV001 Hemophilia A - Phase III - 25% of progress PHASE III
ST400
Beta Thalassemia
ZFN gene editing ST400 Beta Thalassemia - Phase I - 100% of progress ST400 Beta Thalassemia - Phase II - 0% of progress ST400 Beta Thalassemia - Phase III - 0% of progress PHASE I/II
BIVV003❅
Sickle Cell Disease
ZFN gene editing BIVV003 Sickle Cell Disease - Phase I - 100% of progress BIVV003 Sickle Cell Disease - Phase II - 0% of progress BIVV003 Sickle Cell Disease  - Phase III - 0% of progress PHASE I/II
Sutimlimab
Immune Thrombocytopenic Purpura
mAb to C1s Sutimlimab Immune Thrombocytopenic Purpura - Phase I - 50% of progress Sutimlimab Immune Thrombocytopenic Purpura - Phase II - 0% of progress Sutimlimab Immune Thrombocytopenic Purpura - Phase III - 0% of progress PHASE I
BIVV020
Cold agglutinin disease
mAb to C1s BIVV020 Cold Agglutinin Disease - Phase I - 50% of progress BIVV020 Cold Agglutinin Disease - Phase II - 0% of progress BIVV020 Cold Agglutinin Disease - Phase III - 0% of progress PHASE I

Multiple Sclerosis & Neurology

Teriflunomide
Relapsing Multiple Sclerosis - Pediatric
small molecule Teriflunomide Relapsing Multiple Sclerosis - Pediatric - Phase I - 100% of progress Teriflunomide Relapsing Multiple Sclerosis - Phase II - 100% of progress Isatuximab 3L Relapsed Refractory Multiple Myeloma (ICARIA)- Phase III - 100% of progress PHASE III
Tolibrutinib
Multiple Sclerosis
BTK inhibitor SAR442168 Multiple Sclerosis- Phase I - 100% of progress Teriflunomide Relapsing Multiple Sclerosis - Phase II - 100% of progress BIVV001 Hemophilia A - Phase III - 25% of progress PHASE III
Venglustat
Parkinson's disease with a GBA mutation
small molecule venglustat Parkinson's disease with a GBA mutation - Phase I - 100% of progress venglustat Parkinson's disease with a GBA mutation - Phase II - 25% of progress venglustat Parkinson's disease with a GBA mutation - Phase III - 0% of progress PHASE II
SAR441344⚜
Multiple Sclerosis
mAb SAR441344 Multiple Sclerosis - Phase I - 50% of progress SAR441344 Multiple Sclerosis - Phase II - 0% of progress SAR441344 Multiple Sclerosis - Phase III - 0% of progress PHASE I

Oncology

Isatuximab
2L Relapsed Refractory Multiple Myeloma (IKEMA)
mAb Isatuximab Relapsed Refractory Multiple Myeloma - Phase I - 100% of progress Isatuximab Relapsed Refractory Multiple Myeloma - Phase II - 100% of progress Isatuximab 3L Relapsed Refractory Multiple Myeloma (ICARIA)- Phase III - 100% of progress PHASE III
Isatuximab
1L Newly Diagnosed Multiple Myeloma Transplant Ineligible (IMROZ)
mAb Isatuximab 1L Newly Diagnosed MM (IMROZ) - Phase I - 100% of progress Isatuximab 1L Newly Diagnosed MM (IMROZ) - Phase II - 100% of progress Isatuximab 1L Newly Diagnosed MM (IMROZ) - Phase III - 25% of progress PHASE III
Isatuximab
Newly Diagnosed Multiple Myeloma Transplant Eligible (GMMG)
mAb Isatuximab Newly Diagnosed MM - Phase I - 100% of progress Isatuximab Newly Diagnosed MM - Phase II - 100% of progress Isatuximab Newly Diagnosed MM - Phase III - 25% of progress PHASE III
Isatuximab
Smoldering Multiple Myeloma (ITHICA)
mAb Isatuximab Smoldering Multiple Myeloma - Phase I - 100% of progress Isatuximab Smoldering Multiple Myeloma - Phase II - 100% of progress Isatuximab Smoldering Multiple Myeloma - Phase III - 50% of progress PHASE III
Cemiplimab^▼
2L Cervical Cancer
mAb Cemiplimab^  2L Cervical Cancer - Phase I - 100% of progress Cemiplimab^  2L Cervical Cancer - Phase II - 100% of progress Cemiplimab^  2L Cervical Cancer - Phase III - 25% of progress PHASE III
Cemiplimab^▼
Adjuvant in Cutaneous Squamous Cell Carcinoma (CSCC)
mAb Cemiplimab^  adjuvant in CSCC - Phase I - 100% of progress Cemiplimab^  adjuvant in CSCC - Phase II - 100% of progress Cemiplimab^  adjuvant in CSCC - Phase III - 25% of progress PHASE III
Cemiplimab^▼
1L Non-small Cell Lung Cancer
mAb Cemiplimab^ Non-small Cell Lung Cancer - Phase I - 100% of progress Cemiplimab^ Non-small Cell Lung Cancer - Phase II - 100% of progress Cemiplimab^ Non-small Cell Lung Cancer - Phase III - 25% of progress PHASE III
Cemiplimab^▼ + Chemotherapy
1L Non-small Cell Lung Cancer
mAb Cemiplimab^▼ + Chemotherapy 1L Non-small Cell Lung Cancer - Phase I - 100% of progress Cemiplimab^▼ + Chemotherapy 1L Non-small Cell Lung Cancer - Phase II - 100% of progress Cemiplimab^▼ + Chemotherapy  1L Non-small Cell Lung Cancer - Phase III - 25% of progress PHASE III
SAR408701
2-3L Non-Small Cell Lung Cancer
ADC SAR408701 Non-Small Cell Lung Cancer - Phase I - 100% of progress SAR408701 Non-Small Cell Lung Cancer - Phase II - 100% of progress SAR408701 Non-Small Cell Lung Cancer - Phase III - 50% of progress PHASE III
SAR408701 + ramucirumab
2-3L Non-Small Cell Lung Cancer
mAb  isatuximab + Cemiplimab^ Relapsed Refractory Multiple Myeloma - Phase I - 100% of progress isatuximab + Cemiplimab^ Relapsed Refractory Multiple Myeloma - Phase II - 50% of progress isatuximab + Cemiplimab^ Relapsed Refractory Multiple Myeloma - Phase III - 0% of progress PHASE II 
Isatuximab + Cemiplimab^
Lymphoma
mAb  isatuximab + Cemiplimab^ Lymphoma - Phase I - 100% of progress isatuximab + Cemiplimab^ Lymphoma - Phase II - 50% of progress isatuximab + Cemiplimab^ Lymphoma - Phase III - 0% of progress PHASE II 
Isatuximab + atezolizumab♕
Metastatic Colorectal Cancer
mAb  isatuximab + atezolizumab^ mCRC- Phase I - 100% of progress isatuximab + atezolizumab^ mCRC - Phase II - 50% of progress isatuximab + atezolizumab^ mCRC - Phase III - 0% of progress PHASE II 
Isatuximab
Patients Awaiting Kidney Transplant
mAb  isatuximab Patients Awaiting Kidney Transplant - Phase I - 100% of progress isatuximab Patients Awaiting Kidney Transplant - Phase II - 50% of progress isatuximab Patients Awaiting Kidney Transplant - Phase III - 0% of progress PHASE II 
Isatuximab
1-2L Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) - Pediatrics
mAb Isatuximab 1-2L AML/ALL - Pediatrics - Phase I - 100% of progress  Isatuximab 1-2L AML/ALL - Pediatrics - Phase II - 50% of progress Isatuximab 1-2L AML/ALL - Pediatrics - Phase III - 0% of progress PHASE II
Cemiplimab^▼
2-L Basal Cell Carcinoma (BCC)
mAb Cemiplimab^ Advanced BCC - Phase I - 100% of progress Cemiplimab^ Advanced BCC - Phase II - 50% of progress Cemiplimab^ Advanced BCC - Phase III - 0% of progress PHASE II
Amcenestrant
Early Breast Cancer
small molecule SAR439859 Breast Cancer adjuvant - Phase I - 100% of progress SAR439859 Breast Cancer adjuvant - Phase II - 50% of progress SAR439859 Breast Cancer adjuvant - Phase III - 0% of progress PHASE II
Amcenestrant
2-3L Metastatic Breast Cancer
small molecule SAR439859 (SERD) Metastatic Breast Cancer- Phase I - 100% of progress SAR439859 (SERD) Metastatic Breast Cancer - Phase II - 25% of progress SAR439859 (SERD) Metastatic Breast Cancer - Phase III - 0% of progress PHASE I
REGN5458^
Relapsed Refractory Multiple Myeloma
bi-specific mAb REGN5458 Relapsed Refractory Multiple Myeloma - Phase I - 50% of progress REGN5458 Relapsed Refractory Multiple Myeloma - Phase II - 0% of progress REGN5458 Relapsed Refractory Multiple Myeloma - Phase III - 0% of progress PHASE I
REGN4018^
Ovarian Cancer
bi-specific mAb REGN4018 Ovarian Cancer - Phase I - 50% of progress REGN4018 Ovarian Cancer - Phase II - 0% of progress REGN4018 Ovarian Cancer - Phase III - 0% of progress PHASE I
SAR442720 + prozimiblumab
Solid Tumors
small molecule SAR442720 Solid tumors - Phase I - 50% of progress SAR442720 Solid tumors - Phase II - 0% of progress SAR442720 Solid tumors - Phase III - 0% of progress PHASE I
SAR440234
Leukemia
multi-specific mAb SAR440234 Leukemia - Phase I - 50% of progress SAR440234 Leukemia - Phase II - 0% of progress SAR440234 Leukemia - Phase III - 0% of progress PHASE I
SAR441000⚙
Solid Tumors
cytokine mRNA SAR441000 Solid Tumors - Phase I - 50% of progress SAR441000 Solid Tumors - Phase II - 0% of progress SAR441000 Solid Tumors - Phase III - 0% of progress PHASE I
SAR439459^ 
Advanced Solid Tumors
mAb SAR439459 + cemiplimab Advanced Solid Tumors- Phase I - 50% of progress SAR439459 + cemiplimab Advanced Solid Tumors - Phase II - 0% of progress SAR439459 + cemiplimab Advanced Solid Tumors - Phase III - 0% of progress PHASE I
Amcenestrant + palbociclib♣
Metastatic Breast Cancer
small molecule SAR439859 + palbociclib Metastatic Breast Cancer - Phase I - 50% of progress SAR439859 + palbociclib Metastatic Breast Cancer  - Phase II - 0% of progress SAR439859 + palbociclib Metastatic Breast Cancer  - Phase III - 0% of progress PHASE I
cemiplimab +REGN4018^♠ 
Ovarian Cancer
mAb cemiplimab +REGN4018 Ovarian Cancer- Phase I - 50% of progress cemiplimab +REGN4018 Ovarian Cancer - Phase II - 0% of progress cemiplimab +REGN4018 Ovarian Cancer - Phase III - 0% of progress PHASE I
SAR442085
Multiple Myeloma
mAb SAR442085 Multiple Myeloma- Phase I - 25% of progress SAR442085 Multiple Myeloma - Phase II - 0% of progress SAR442085 Multiple Myeloma - Phase III - 0% of progress PHASE I
 SAR442257
Multiple Myeloma / Non-Hodgkin's Lymphoma
tri-specific mAb  SAR442085 Multiple Myeloma- Phase I - 25% of progress      PHASE I
REGN5459♠ 
Relapsed Refractory Multiple Myeloma
bi-specific mAb REGN5459 Relapsed Refractory Multiple Myeloma - Phase I - 25% of progress REGN5459 Relapsed Refractory Multiple Myeloma - Phase II - 0% of progress REGN5459 Relapsed Refractory Multiple Myeloma - Phase III - 0% of progress PHASE I
SAR442720 + cobimetinib
Relapsed Refractory Solid Tumors
bi-specific mAb SAR442720 + cobimetinib Relapsed Refractory Solid Tumors - Phase I - 25% of progress SAR442720 + cobimetinib Relapsed Refractory Solid Tumors - Phase II - 0% of progress SAR442720 + cobimetinib Relapsed Refractory Solid Tumors - Phase III - 0% of progress PHASE I
SAR444245 (THOR-707)
Solid Tumors
non-alpha IL-2 
TSAR444245 (THOR-707) Solid Tumors - Phase I - 25% of progress SAR444245 (THOR-707) Solid Tumors - Phase II - 0% of progress SAR444245 (THOR-707) Solid Tumors - Phase III - 0% of progress PHASE I

Immunology

Dupilumab^
Atopic Dermatitis (6 mo - 5 years old)
mAb Dupixent Polyarticular Juvenile Idiopathic Atopic Dermatitis (6 mo - 5 years old) - Phase I - 100% of progress Dupixent Polyarticular Juvenile Idiopathic Atopic Dermatitis (6 mo - 5 years old) - Phase II - 100% of progress Fitusiran* Hemophilia A & B - Phase III - 50% of progress PHASE III
Dupilumab^
Asthma (6-11 years old)
mAb Dupilumab^ Asthma - Phase I - 100% of progress Dupilumab^ Asthma - Phase II - 100% of progress Fitusiran* Hemophilia A & B - Phase III - 50% of progress PHASE III
Dupilumab^
Eosinophilic Esophagitis
mAb Dupilumab^ Eosinophilic esophagitis - Phase I - 100% of progress Dupilumab^ Eosinophilic esophagitis - Phase II - 100% of progress Dupilumab^ Eosinophilic esophagitis - Phase III - 25% of progress PHASE III
Dupilumab^
Bullous pemphigoid
mAb Dupixent Bullous pemphigold - Phase I - 100% of progress Dupixent PBullous pemphigold - Phase II - 100% of progress Dupixent Bullous pemphigold - Phase III - 25% of progress PHASE III
Dupilumab^
Prurigo nodularis
mAb Dupixent Prurigo nodularis - Phase I - 100% of progress Dupixent Prurigo nodularis - Phase II - 100% of progress Dupixent Prurigo nodularis - Phase III - 25% of progress PHASE III
Dupilumab^
Chronic spontaneous urticaria
mAb Dupixent Chronic spontaneous uticaria - Phase I - 100% of progress Dupixent Chronic spontaneous uticaria - Phase II - 100% of progress Dupixent Chronic spontaneous uticaria - Phase III - 25% of progress PHASE III
Rizabrutinib
Pemphigus
BTK inhibitor Sarilumab^ Polymyalgia Rheumatica - Phase I - 100% of progress Sarilumab^ Polymyalgia Rheumatica - Phase II - 100% of progress Sarilumab^ Polymyalgia Rheumatica - Phase III - 25% of progress PHASE III
Dupilumab^
COPD
mAb Dupilumab COPD - Phase I - 100% of progress Dupilumab COPD - Phase II - 100% of progress Dupilumab COPD - Phase III - 25% of progress PHASE III
Dupilumab^
Grass Pollen Allergy
mAb Dupilumab^ Grass Pollen Allergy - Phase I - 100% of progress Dupilumab^ Grass Pollen Allergy - Phase II - 50% of progress Dupilumab^ Grass Pollen Allergy- Phase III - 0% of progress PHASE II
Dupilumab^
Peanut Allergy
mAb Dupilumab^ Peanut Allergy- Phase I - 100% of progress Dupilumab^ Peanut Allergy- Phase II - 50% of progress Dupilumab^ Peanut Allergy- Phase III - 0% of progress PHASE II
 Rizabrutinib
Immune Thrombocytopenia
 BTK inhibitor Dupilumab^ Peanut Allergy- Phase I - 100% of progress SAR440340 Asthma - Phase II - 25% of progress    PHASE II
 Rizabrutinib
IgG4-related disease
 BTK inhibitor Dupilumab^ Peanut Allergy- Phase I - 100% of progress SAR440340 Asthma - Phase II - 25% of progress    PHASE II
Itepekimab^
Asthma
mAb SAR440340 Asthma - Phase I - 100% of progress SAR440340 Asthma - Phase II - 25% of progress SAR440340 Asthma - Phase III - 0% of progress PHASE II
Itepekimab^
COPD
mAb SAR440340 COPD - Phase I - 100% of progress SAR440340 COPD - Phase II - 25% of progress SAR440340 COPD - Phase III - 0% of progress PHASE II
Sarilumab^
Polyarticular Juvenile Idiopathic Arthritis
mAb Sarilumab Polyarticular Juvenile Idiopathic Arthritis - Phase I - 100% of progress Sarilumab Polyarticular Juvenile Idiopathic Arthritis - Phase II - 25% of progress Sarilumab Polyarticular Juvenile Idiopathic Arthritis - Phase III - 0% of progress PHASE II
Sarilumab^
Systemic Juvenile Arthritis
mAb Sarilumab Systemic Juvenile Arthritis - Phase I - 100% of progress Sarilumab Systemic Juvenile Arthritis - Phase II - 25% of progress Sarilumab Systemic Juvenile Arthritis - Phase III - 0% of progress PHASE II
Romilkimab
Systemic Scleroderma
bi-specific mAb Romilkimab Systemic Scleroderma - Phase I - 100% of progress Romilkimab Systemic Scleroderma - Phase II - 25% of progress Romilkimab Systemic Scleroderma - Phase III - 0% of progress PHASE II
SAR441169
Psoriasis
small molecule Systemic Scleroderma - Phase I - 100% of progress SSystemic Scleroderma - Phase II - 0% of progress Systemic Scleroderma - Phase III - 0% of progress PHASE I
SAR441236
HIV
mAb SAR441236 HIV - Phase I - 25% of progress SAR441236 HIV - Phase II - 0% of progress SAR441236 HIV - Phase III - 0% of progress PHASE I
SAR443122
Inflammatory Indications
RIPK1 inhibitor SAR443122 Systemic Inflammatory disease - Phase I - 25% of progress SAR443122 Systemic Inflammatory disease - Phase II - 0% of progress SAR443122 Systemic Inflammatory disease - Phase III - 0% of progress PHASE I
PRN473
Immune mediated diseases 
 BTK inhibitor SAR443122 Systemic Inflammatory disease - Phase I - 25% of progress     PHASE I 

The agents mentioned here are investigational and have not been approved by the US Food and Drug Administration (FDA) or any other regulatory agency worldwide for the uses under investigation.

Scientist at microscope
Sanofi’s R&D portfolio
The full Sanofi research pipeline focuses on finding innovative solutions to a variety of major public health challenges.

This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.

Click here for more information on cookies.
OK